DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $99,749,101 | +1.7% | 402,052 | -1.6% | 0.25% | +10.1% |
Q2 2023 | $98,057,280 | -10.6% | 408,572 | -6.1% | 0.23% | -15.0% |
Q1 2023 | $109,644,961 | -3.5% | 435,030 | +1.6% | 0.27% | -9.8% |
Q4 2022 | $113,671,158 | +7.8% | 428,269 | +4.9% | 0.30% | +0.3% |
Q3 2022 | $105,410,000 | +1.5% | 408,107 | -0.4% | 0.30% | +10.9% |
Q2 2022 | $103,844,000 | -4.6% | 409,609 | +10.3% | 0.27% | +6.8% |
Q1 2022 | $108,884,000 | -14.7% | 371,202 | -4.3% | 0.25% | -5.3% |
Q4 2021 | $127,663,000 | +8.4% | 388,023 | +0.3% | 0.26% | +3.1% |
Q3 2021 | $117,781,000 | +10.0% | 386,878 | -3.0% | 0.26% | +12.8% |
Q2 2021 | $107,055,000 | +11.0% | 398,925 | -6.9% | 0.23% | +6.1% |
Q1 2021 | $96,470,000 | -17.8% | 428,708 | -18.8% | 0.21% | -10.1% |
Q4 2020 | $117,346,000 | +0.8% | 528,253 | -2.3% | 0.24% | -9.5% |
Q3 2020 | $116,472,000 | +20.4% | 540,900 | -1.2% | 0.26% | +12.0% |
Q2 2020 | $96,766,000 | +22.4% | 547,230 | -4.2% | 0.23% | +1.7% |
Q1 2020 | $79,053,000 | -7.7% | 571,147 | +2.3% | 0.23% | +12.7% |
Q4 2019 | $85,661,000 | +4.7% | 558,135 | -3.3% | 0.20% | -2.4% |
Q3 2019 | $81,841,000 | +4.7% | 577,394 | +4.9% | 0.21% | -21.4% |
Q2 2019 | $78,134,000 | +13.1% | 550,318 | +3.5% | 0.27% | +4.7% |
Q1 2019 | $69,067,000 | +25.8% | 531,941 | -0.1% | 0.25% | +11.4% |
Q4 2018 | $54,885,000 | -6.4% | 532,243 | -1.4% | 0.23% | +9.6% |
Q3 2018 | $58,656,000 | -55.2% | 539,809 | -59.3% | 0.21% | -6.7% |
Q2 2018 | $130,946,000 | +4.1% | 1,326,981 | +3.3% | 0.22% | +0.5% |
Q1 2018 | $125,774,000 | +6.0% | 1,284,590 | +0.5% | 0.22% | +7.8% |
Q4 2017 | $118,684,000 | +8.5% | 1,278,651 | +0.3% | 0.21% | +2.0% |
Q3 2017 | $109,381,000 | +1.7% | 1,275,133 | +0.0% | 0.20% | -2.9% |
Q2 2017 | $107,588,000 | -0.7% | 1,274,885 | +0.6% | 0.21% | -3.7% |
Q1 2017 | $108,338,000 | +9.5% | 1,266,662 | -0.4% | 0.22% | +3.8% |
Q4 2016 | $98,983,000 | -0.7% | 1,271,626 | +0.0% | 0.21% | +0.5% |
Q3 2016 | $99,641,000 | -20.4% | 1,271,099 | +2.6% | 0.21% | -24.7% |
Q2 2016 | $125,135,000 | +7.7% | 1,238,958 | +1.2% | 0.28% | +5.4% |
Q1 2016 | $116,187,000 | +4.0% | 1,224,830 | +1.9% | 0.26% | +2.4% |
Q4 2015 | $111,690,000 | +8.8% | 1,202,515 | -0.2% | 0.26% | +2.0% |
Q3 2015 | $102,644,000 | -2.3% | 1,204,604 | -1.9% | 0.25% | +3.7% |
Q2 2015 | $105,098,000 | +3.5% | 1,227,922 | +2.6% | 0.24% | +2.1% |
Q1 2015 | $101,579,000 | +2.1% | 1,196,452 | +3.0% | 0.24% | +0.4% |
Q4 2014 | $99,528,000 | +14.9% | 1,161,213 | +1.9% | 0.24% | +11.4% |
Q3 2014 | $86,617,000 | -8.9% | 1,139,997 | -5.6% | 0.21% | -3.7% |
Q2 2014 | $95,037,000 | +12.5% | 1,207,126 | +7.2% | 0.22% | +6.8% |
Q1 2014 | $84,477,000 | -2.0% | 1,126,365 | +0.9% | 0.20% | -3.8% |
Q4 2013 | $86,179,000 | +10.1% | 1,116,313 | -1.2% | 0.21% | +1.9% |
Q3 2013 | $78,295,000 | +9.6% | 1,129,470 | +0.1% | 0.21% | +4.0% |
Q2 2013 | $71,458,000 | – | 1,128,871 | – | 0.20% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |